2022 American Transplant Congress
Final Flow and Resistance with Cold Pulsatile Perfusion Preservation Are Independent Risk Factors for Dialysis in the First Week Post-Transplant, Analysis of SRTR Data
Kidney Transplant, Ascension Sacred Heart Hospital, Pensacola, FL
*Purpose: To determine if final flow or resistance on cold pulsatile perfusion preservation (CPPP) have independent predictive value for dialysis in the first week post-transplant.*Methods:…2022 American Transplant Congress
Testing an Education Only Intervention to Increase Willingness and Pursuit of Living Donor Kidney Transplantation
*Purpose: The Talking About Live Kidney Donation (TALK) intervention uses an educational video and booklet to improve consideration and pursuit of LDKT in kidney failure…2022 American Transplant Congress
Blood Transcriptomes of Covid-19 Infected Kidney Recipients Demonstrate Frequent and Persistent Sars-cov-2 Virome Gene Expression
*Purpose: Kidney transplant recipients (KTRs) have poor outcomes vs non-KTRs with acute COVID-19. To provide insight into management of immunosuppression during acute COVID-19, we studied…2022 American Transplant Congress
Alloreactive Regulatory T Cells Release Distinct Subpopulations of Extracellular Vesicles Bearing Immune Regulatory Proteins and the TCR/CD3 Complex Under Antigen Specific Stimulation
Brigham and Women's Hospital, Boston, MA
*Purpose: Extracellular vesicles (EVs) are vital mediators of intercellular communication, playing an important role in the immune synapse and the T cell response. However, regulatory…2022 American Transplant Congress
Use of Dd-cfdna to Guide Tapering of Immunosuppression Therapy in Kidney Transplant Recipients
1Victoria Kidney and Dialysis Associates, Victoria, TX, 2Natera, Inc., Austin, TX
*Purpose: Continuous administration of immunosuppressive therapy (IST) is required to avoid allograft rejection in transplant recipients. However, these therapeutic interventions can lead to significant side…2022 American Transplant Congress
Conversion from Immediate to Extended-Release Tacrolimus (LCP-Tac) Six Months After Renal Transplantation Optimizes Safety and Efficacy
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for prevention of rejection in kidney transplant recipients (KTRs) that may have less variability and…2022 American Transplant Congress
Low Fixed Tacrolimus Starting Dose and the Correlation with Renal Allograft Rejection
David Geffen School of Medicine, Los Angeles, CA
*Purpose: Achieving a tacrolimus therapeutic trough concentration (C0) by post-operative day (POD) 3-7 has been associated with a reduced risk for rejection. Although FDA prescribing…2022 American Transplant Congress
Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression
University of Utah Health, Salt Lake City, UT
*Purpose: The demand for kidney transplant continues to rise, and limited supply has encouraged acceptance of marginal donor organs, such as those at risk for…2022 American Transplant Congress
Patient Reported Outcomes Following Renal Transplantation: The Future of Holistic Post-Transplant Care
*Purpose: Patients with renal disease prioritise symptoms and functionality over the biochemistry and clinical guidelines, which clinicians traditionally rely on. Whilst kidney transplantation is expected…2022 American Transplant Congress
Acute Tubular Injury and Necrosis Do Not Lead to Meaningful Elevations in Donor-Derived Cell-Free DNA (dd-cfDNA)
*Purpose: Associations between non-rejection histologic diagnoses and dd-cfDNA have not been extensively characterized. We explored these associations in kidney transplant recipients enrolled in the Kidney…
- « Previous Page
- 1
- …
- 41
- 42
- 43
- 44
- 45
- …
- 531
- Next Page »